

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
23 August 2001 (23.08.2001)

PCT

(10) International Publication Number
WO 01/60380 A1

(51) International Patent Classification⁷: A61K 31/70,
31/44, 31/425, 31/415, 31/355, 31/34, 31/17, 31/115

(21) International Application Number: PCT/US01/04538

(22) International Filing Date: 12 February 2001 (12.02.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/504,830 16 February 2000 (16.02.2000) US

(71) Applicant: PHOENIX SCIENTIFIC, INC. [US/US];
3915 South 48th Street Terrace, St. Joseph, MO
64506-0457 (US).

(72) Inventor: MIHALIK, Richard; 2520 Felix Street, St.
Joseph, MO 64501 (US).

(74) Agents: WHARTON, Susan, J. et al.; Shook, Hardy &
Bacon L.L.P., One Kansas City Place, 1200 Main Street,
Kansas City, MO 64105-2118 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: A PARASITICIDAL FORMULATION AND A METHOD OF MAKING THIS FORMULATION

(57) **Abstract:** A parasiticial formulation is provided. This formulation includes a pyrrolidone solvent, a bridging solvent, and a parasiticial agent. One or more parasiticial agents may be included in the formulation. Preferably, the formulation contains both closantel and ivermectin. Another aspect of the present invention is a method of making this parasiticial formulation. This method includes mixing a pyrrolidone solvent and a bridging solvent to form a solvent solution and adding one or more parasiticial agents to the solvent solution. A further aspect of the present invention is a method for administering the parasiticial formulation of the present invention to an animal. This method of administration includes providing the parasiticial formulation described above and applying this formulation to the skin of an animal, wherein the formulation is absorbed through the animal's skin.



WO 01/60380 A1

- 1 -

A PARASITICIDAL FORMULATION AND A METHOD OF MAKING THIS FORMULATION

BACKGROUND OF THE INVENTION

The present invention relates to a parasiticide formulation and a method
5 for making the formulation. More specifically, the present invention relates to a
parasiticide formulation for use in veterinary applications.

Currently, closantel, a parasiticide agent, is available in an injectable form
or as an oral drench. One disadvantage with these closantel parasiticide formulations is
that they are not available in a pour-on form.

10 Ivermectin, another parasiticide agent which kills different parasites from
closantel, may be purchased in an injectable form, as a pour-on formulation, in a paste
form, as an oral drench, or in a chewable form. The ivermectin injectable formulations
currently available contain glycerol formal or propylene glycol to dissolve the ivermectin.
The ivermectin pour-on formulations currently available contain isopropyl alcohol or a
15 mixture of caprylic acids and caprylic esters to dissolve the ivermectin.

One disadvantage with both injectable and pour-on ivermectin
formulations currently available is that none of these formulations will dissolve closantel
and like parasiticide formulations in concentrations sufficient to be useful. Another
disadvantage with the ivermectin pour-on formulations available is that they only have
20 up to a 0.5% weight per volume (w/v) concentration of ivermectin.

Additionally, a disadvantage with parasiticide formulations currently
available is that closantel and ivermectin are not available in a single formulation, and
therefore a broadened spectrum of parasite protection is not available in a single
formulation. Still further, parasiticide agents, including, but not limited to closantel and
25 ivermectin, cannot be combined in pour-on formulations currently available in a manner
that keeps both parasiticide agents in solution.

In order to overcome these disadvantages, a parasiticide formulation
containing an effective solvent delivery system that allows one or more parasiticide
agents to dissolve, especially closantel and ivermectin in combination, is needed. In
30 addition, the resulting parasiticide formulation should be usable in a pour-on or an

injectable form. Still further, the solvent delivery system should be able to hold larger amounts of parasitocidal agents than prior formulations.

SUMMARY OF THE INVENTION

It is an object of the present invention to provide a parasitocidal
5 formulation containing more than one parasitocidal agent or a larger amount of a single parasitocidal agent than conventional formulations that may be administered as a pour-on product in order to facilitate easier administration of the parasitocidal formulation.

It is another object of the present invention to provide a parasitocidal
formulation that contains at least two different parasitocidal agents so as to obtain a
10 broadened spectrum of parasite protection.

It is a further object of the present invention to provide a method of making a parasitocidal formulation that achieves the foregoing objects.

Still another object of the present invention is to provide a method for administering a parasitocidal formulation that achieves the foregoing objects.

15 According to the present invention, the foregoing and other objects are achieved by a pour-on or an injectable parasitocidal formulation that includes a mixture of a pyrrolidone solvent, a bridging solvent and at least one parasitocidal agent. One or more parasitocidal agents may be included in the formulation. Preferably, the formulation contains both closantel and ivermectin. Another aspect of the present invention is a
20 method of making this parasitocidal formulation. This method includes mixing a pyrrolidone solvent and a bridging solvent to form a solvent solution and adding one or more parasitocidal agents to the solvent solution. A further aspect of the present invention is a method for administering the parasitocidal formulation of the present invention to an animal. This method of administration includes providing the
25 parasitocidal formulation described above and applying this formulation to the skin of an animal, wherein the formulation may be absorbed through the animal's skin.

Additional objects, advantages and novel features of the invention will be set forth in part in the description which follows, and in part will become apparent to those skilled in the art upon examination of the following, or may be learned from the
30 practice of the invention. The objects and advantages of the invention may be realized

and attained by means of the instrumentalities and combinations particularly pointed out in the appended claims.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

5 The parasiticial formulation of the present invention is an effective pour-on or injectable formulation for protection against parasites. The formulation includes a solvent delivery system and one or more parasiticial agents. The solvent delivery system includes a mixture of a pyrrolidone solvent and a bridging solvent. This mixture provides a unique solvent system which allows one or more parasiticial agents to dissolve effectively when added to the solvents.

10 The pyrrolidone solvent that may be used in the formulation of the present invention includes, but is not limited to, N-methyl-2-pyrrolidone, 2-pyrrolidone, N,5-dimethyl-2-pyrrolidone, 3,3-dimethyl-2-pyrrolidone, N-ethyl-2-pyrrolidone, N-ethoxy-2-pyrrolidone, N-ethylene-2-pyrrolidone, 1-pyrrolidone, or any combinations thereof. Preferably, the pyrrolidone solvent is N-methyl-2-pyrrolidone or 2-pyrrolidone. The
15 pyrrolidone solvent desirably is present in the solvent delivery system in an amount effective, in combination with a bridging solvent, for dissolving a therapeutic amount of one or more parasiticial agents.

 The bridging solvent that may be used in the formulation of the present invention includes, but is not limited to, diethylene glycol monobutyl ether (DGME),
20 benzyl benzoate, isopropyl alcohol, xylenes, or any combinations thereof. If xylenes are used, usually a combination of ortho-xylene, meta-xylene and para-xylene is used. The bridging solvent aids in dissolving the parasiticial agents and acts to carry the formulation through an animal's skin once it is applied to the skin. If 2-pyrrolidone is used as the pyrrolidone solvent, then preferably xylenes are used as the bridging solvent.
25 If a pyrrolidone solvent other than 2-pyrrolidone is used, then the preferred bridging solvent is DGME. In any event, the solvent delivery system must include an amount of the bridging solvent that is effective, in combination with the pyrrolidone solvent, to dissolve a therapeutic amount of the active parasiticial agent or agents.

 The combination of a pyrrolidone solvent and a bridging solvent to form
30 the unique solvent delivery system of the present invention allows one or more

parasitocidal agents to dissolve. The solvent system dissolves the parasitocidal agents and keeps them in solution. The solvent delivery system also functions to transport one or more parasitocidal agents into an animal so that the agent or agents may interact therapeutically with parasites in the animal.

5 The parasitocidal agents that may be used in the formulation of the present invention include, but are not limited to, closantel, oxclozanide, praziquantel, pyrantels, tetrahydropyrimidines, probenzimidazoles, imidazothiazoles, macrocyclic lactones, benzimidazoles, tetramisoles, avermectins, epsiprantel, morantel, febantel, netobimin, clorsulon, bunamidine, nitroscanate, melarsomine, amidines, benzoyl urea derivatives,
10 carbamates, nitroquanidines, pyrazoles, pyrethrins, pyrethroids, pyriproxyfen, acylhydrazones and any combinations thereof.

 An example of a pyrantel that may be used is pyrantel pamoate. Examples of benzimidazoles that may be used include, but are not limited to, mebendazole, oxibendazole, fenbendazole, oxfendazole, triclabendazole, flubendazole, ricobendazole,
15 thiabendazole, and albendazole. Preferably, if a tetramisole is used, it is levamisole. Examples of avermectins that may be used include, but are not limited to, ivermectin, moxidectin, doramectin, eprinomectin, and milbemycin. Preferably, a combination of ivermectin and closantel is used as the parasitocidal agent in the formulation. Ivermectin kills a variety of internal and external parasites; a number of worms including stomach
20 worms, intestinal worms, lungworms, barber's pole worms, lice, and mites. Closantel kills adult and immature barber's pole worms, liver flukes, and all stages of nasal bot in sheep. Most preferably, the formulation contains ivermectin and closantel in about a 1:10 ratio.

 As discussed above, closantel and ivermectin each provide protection
25 against different species of parasites. Thus, when closantel and ivermectin are combined in a single parasitocidal formulation, the formulation provides protection against a broader spectrum of parasites than a formulation containing either parasitocidal agent alone. Additionally, because the solvent delivery system of the present invention effectively dissolves both closantel and ivermectin, if either active ingredient is used in the absence
30 of the other, the solvent delivery system of the present invention may still be used. When used with a single parasitocidal agent, including but not limited to ivermectin or

closantel, the solvent delivery system of the present invention may allow the parasitocidal agent to dissolve at a higher concentration than formulations currently available. For example, an ivermectin formulation with a concentration of ivermectin from about 1-5% w/v or higher may be made. Thus, the solvent delivery system of the present invention
5 allows for several formulations, each manufactured to provide protection against a targeted parasite population.

The preferred total amount of parasitocidal agent in the formulation of the present invention may be about 0.1-15% w/v, whether used singularly or in combination. Preferably, the formulation of the present invention includes about 1-8% w/v parasitocidal
10 agent.

When using closantel and ivermectin in combination, the parasitocidal formulation of the present invention preferably may include about 1-10% w/v closantel and about 0.1-5% w/v ivermectin. More preferably, the formulation of the present invention may include about 3-7% w/v closantel and about 0.3-0.7% w/v ivermectin.
15 Most preferably, the formulation of the present invention may include about 5% w/v closantel and about 0.5% w/v ivermectin.

If the chosen pyrrolidone solvent is N-methyl-2-pyrrolidone, the parasitocidal formulation of the present invention preferably may include about 5-90% w/v N-methyl-2-pyrrolidone. More preferably, it includes about 30-50% w/v N-methyl-2-pyrrolidone. Most preferably, it may include about 40-45% w/v N-methyl-2-pyrrolidone. However, when increased amounts of closantel are used in the formulation, the amount of N-methyl-2-pyrrolidone may also be increased to ensure that the closantel dissolves. Thus, amounts at the higher ends of the ranges given are used.
20

If the chosen pyrrolidone solvent is 2-pyrrolidone, the parasitocidal
25 formulation of the present invention preferably may include about 15-90% w/v 2-pyrrolidone. More preferably, it may include about 50-80% w/v 2-pyrrolidone. Most preferably, it may include about 70% w/v 2-pyrrolidone.

If any pyrrolidone solvent other than N-methyl-2-pyrrolidone or 2-pyrrolidone is chosen, the parasitocidal formulation of the present invention preferably
30 may include about 10-90% w/v pyrrolidone solvent. More preferably, it may include about 30-70% w/v pyrrolidone solvent.

If the chosen bridging solvent is DGME, the parasitocidal formulation of the present invention may preferably include about 10-90% w/v DGME. More preferably, it may include about 25-75% w/v DGME. Most preferably, it may include about 50% w/v DGME. If any bridging solvent other than DGME is chosen, either
5 singularly or in combination, the parasitocidal formulation of the present invention preferably may include about 10-90% w/v bridging solvent. More preferably, it may include about 30-70% w/v bridging solvent. Most preferably, it may include about 50% w/v bridging solvent.

While the solvent delivery system and a parasitocidal agent are the only
10 components necessary in the formulation of the present invention, a number of optional ingredients may be added to enhance certain properties of the formulation. One such optional ingredient is a stabilizer which acts to enhance the stability of the parasitocidal formulation. Stabilizers that may be used in the formulation of the present invention include, but are not limited to, vitamin B₁₂, vitamin E acetate, niacinamide, ascorbic acid,
15 butylated hydroxyaniline, thioctic acid, sorbic acid, sodium formaldehyde sulfoxylate, butylated hydroxytoluene, or any combinations thereof. Preferably, vitamin B₁₂ and vitamin E acetate, either singularly or in combination, are used as stabilizers in the formulation of the present invention because they are the most effective in preserving the active ingredients.

20 If vitamin B₁₂ is chosen as a stabilizer for the formulation, the parasitocidal formulation of the present invention preferably may include about 0.005-1% w/v vitamin B₁₂. More preferably, it may include about 0.01-0.5% w/v vitamin B₁₂. Most preferably, it may include about 0.1% w/v vitamin B₁₂.

If vitamin E acetate is chosen as a stabilizer for the formulation, the
25 parasitocidal formulation of the present invention preferably may include about 0.05-5% w/v vitamin E acetate. More preferably, it may include about 0.5-1.5% w/v vitamin E acetate. Most preferably, it may include about 1% w/v vitamin E acetate.

If any stabilizer other than vitamin B₁₂ or vitamin E acetate is used in the formulation, the formulation of the present invention preferably may include about
30 0.005%-15% w/v stabilizer. More preferably, it may include about 0.05-3% w/v stabilizer. These ranges of stabilizers also may apply if two or more of the stabilizers are

used in combination, such as when vitamin B₁₂ and vitamin E acetate are used in combination.

Another optional ingredient that may be included in the formulation of the present invention is a solubility agent. Solubility agents of the present invention may include, but are not limited to, mixtures of caprylic acids and esters, ethyl oleate, propylene glycol, Arachis oil (peanut oil), or any combinations thereof. The mixtures of caprylic acids and esters may contain from about 99% acids to about 99% esters. Solubility agents aid in dissolving the active ingredients of the formulation, but also aid in spreading the formulation across an animal's skin once it has been poured over the skin, making the formulation less aggressive to the skin. Still further, because each of these solubility agents are oily substances used in the formulation, they help the skin retain moisture.

The parasiticial formulation of the present invention preferably may include about 5-50% w/v solubility agent. More preferably, the formulation of the present invention may include about 10-35% w/v solubility agent. Most preferably, the formulation of the present invention may include about 20% w/v solubility agent.

Another ingredient that optionally may be added to the formulation of the present invention is a colorant. Colorants give the formulation a more consistent color and aid an observer in determining what areas of an animal's skin have been treated. A colorant may be added to the parasiticial formulation of the present invention in an amount sufficient that the formulation poured onto the animal's skin can be seen. In addition, water may be added to the formulation of the present invention. In fact, it may be necessary to add water to the formulation if a colorant is added so that the colorant is adequately dispersed. Further, a pH stabilizer may be added to the parasiticial formulation of the present invention to prevent hydrolysis. Examples of pH stabilizers that may be used in conjunction with the present invention include, but are not limited to, triethanolamine and diethanolamine.

One preferred formulation of the present invention includes N-methyl-2-pyrrolidone, DGME, closantel, and ivermectin. Another preferred formulation of the present invention includes 2-pyrrolidone, xylenes, closantel, and ivermectin. A highly preferred formulation of the present invention is described in Example 1.

The parasiticial formulation of the present invention is made by combining a pyrrolidone solvent, a bridging solvent, and one or more parasiticial agents to form a mixture. Preferably, closantel and ivermectin may be used in combination as the parasiticial agents. The order in which components are added in making the
5 formulation is not critical. The formulation may optionally be heated to between about 40° and 80°C continuously or intermittently during its preparation in order to dissolve the components more quickly. If vitamin B₁₂ is used as a stabilizer, it is recommended that the formulation may be heated to about 50°C prior to adding the vitamin B₁₂. Preferably, a portion of the pyrrolidone solvent, the bridging solvent, or the solubility
10 agent may be added last so that a specific quantity of parasiticial formulation may be obtained and to ensure that all ingredients dissolve. This process can be scaled to make any desired quantity of the formulation.

One preferred method of making the parasiticial formulation of the present invention includes placing a quantity of pyrrolidone solvent in a vessel and
15 warming it to about 50°C. Next, a stabilizer is added, and the resulting solution is cooled to room temperature. The bridging solvent is then added and mixed into the solution for an effective period of time. Optionally, a second stabilizer may then be added and mixed until all ingredients are adequately dissolved. Following this, ivermectin is added and mixed into the solution until it is dissolved. Closantel is then added, and the mixture is
20 agitated until a portion of the closantel is dissolved. The closantel likely will not completely dissolve. Thus, it will be necessary to add an additional portion of pyrrolidone solvent to ensure that all components adequately dissolve.

The parasiticial formulation of the present invention may be administered as a pour-on product or as an injectable formulation to any animal. Preferably, it is
25 administered as a pour-on product. It is especially useful for cattle, horses, sheep, goats, and pigs. Most preferably, it is administered to cattle. It may be poured over an animal's back or may be poured on any other body part of an animal that needs treatment. Preferably, it may be administered in a dosage of about 0.02-0.4 milliliters of formulation per kilogram of animal. More preferably, it may be administered in a dosage of about
30 0.02-0.3 milliliters of formulation per kilogram of animal. Most preferably, it may be

administered in a dosage of about 0.02-0.25 milliliters of formulation per kilogram of animal.

The following are examples of various parasiticial formulations and methods of making these formulations that are within the scope of this invention. These
5 examples are not meant in any way to limit the scope of this invention.

EXAMPLE 1

N-methyl-2-pyrrolidone was added to a vessel and warmed to 50°C. Agitation began. With continued agitation, a quantity of vitamin B₁₂ amounting to 0.1% w/v of the final formulation was added to the solvent and mixed with it until the vitamin
10 B₁₂ dissolved. The resulting solution was then cooled to room temperature. A quantity of DGME amounting to 50% w/v of the final formulation was then added and mixed into the solution. Next, vitamin E acetate was added in a quantity amounting to 1% w/v of the final formulation, and the resulting solution was mixed until all ingredients were adequately dissolved. With continued agitation, a quantity of ivermectin amounting to
15 0.5% w/v of the final formulation was added and mixed into the solution until dissolved. Closantel was then added in a quantity amounting to 5% w/v of the final formulation, and the mixture was agitated to dissolve a portion of the closantel. With continued agitation, a supplemental amount of N-methyl-2-pyrrolidone was added in an amount sufficient to completely dissolve the closantel. The total amount of N-methyl-2-pyrrolidone used
20 made up the balance of the formulation.

EXAMPLE 2

A quantity of xylenes was added to a vessel. To the xylenes, a quantity of 2-pyrrolidone amounting to 70% w/v of the final formulation was added and agitation began. With continued agitation, a quantity of ivermectin amounting to 0.5% w/v of the
25 final formulation was added and mixed into the solution until dissolved. Next, closantel was added in a quantity amounting to 5% w/v of the final formulation, and the mixture was agitated to dissolve a portion of the closantel. With continued agitation, a supplemental amount of xylenes was added in an amount sufficient to completely

dissolve the closantel. The total amount of xylenes used made up the balance of the formulation.

EXAMPLE 3

A quantity of xylenes was added to a vessel. Agitation began. With
5 continued agitation, a quantity of N-methyl-2-pyrrolidone amounting to 18.2% w/v of
the final formulation was added. Next, a quantity of a mixture of caprylic acids and
esters (obtained from Croda, Inc. of Parsippany, New Jersey under the tradename
Crodamol Cap™) amounting to 18.2% w/v of the final formulation was added and mixed
with the solution until the Crodamol Cap™ dissolved. Subsequently, a quantity of
10 vitamin E acetate amounting to 0.93% w/v of the final formulation was added. With
continued agitation, diethanolamine was added in a quantity amounting to 0.16% w/v to
the solution and mixed until dissolved. Next, a quantity of Arachis oil amounting to
16% w/v of the final formulation was added and mixed until dissolved. Following this,
a quantity of ivermectin amounting to 0.45% w/v of the final formulation was added and
15 mixed into the solution until dissolved. Closantel was then added in a quantity
amounting to 4.5% w/v, and the mixture was agitated for a time sufficient to dissolve a
portion of the closantel. With continued agitation, a supplemental amount of xylenes was
added in an amount sufficient to completely dissolve the closantel. The total amount of
xylenes used made up the balance of the formulation.

20

EXAMPLE 4

A quantity of N-methyl-2-pyrrolidone was added to a vessel. Agitation
began. With continued agitation, a quantity of isopropyl alcohol amounting to 20% w/v
of the final formulation was added, and the two solvents were mixed into solution. Next,
25 a quantity of ethyl oleate amounting to 20% w/v of the final formulation was added, and
the mixture was agitated until all ingredients were adequately dissolved. Subsequently,
a quantity of DGME amounting to 20% w/v of the final formulation was added. Next,
a quantity of benzyl benzoate amounting to 20% w/v of the final formulation was added.
Following this, a quantity of vitamin E acetate amounting to 1% w/v of the final
30 formulation was added, and the solution mixed until all components adequately

dissolved. With continued agitation, a quantity of ivermectin amounting to 0.5% w/v of the final formulation was added. Subsequently, a quantity of closantel amounting to 5% w/v of the final formulation was added, and the mixture was agitated to dissolve a portion of the closantel. With continued agitation, a supplemental amount of N-methyl-2-pyrrolidone was added in an amount sufficient to completely dissolve all of the closantel. The total amount of N-methyl-2-pyrrolidone used made up the balance of the formulation.

EXAMPLE 5

A quantity of N-methyl-2-pyrrolidone was added to a vessel. Agitation began. To the N-methyl-2-pyrrolidone, a quantity of benzyl benzoate amounting to 44.3% w/v of the final formulation was added, and the mixture was agitated to ensure all ingredients dissolved. With continued agitation, a quantity of ethyl oleate amounting to 30% w/v of the final formulation was added. Next, a quantity of ivermectin amounting to 0.5% w/v of the final formulation was added, and the mixture was agitated until all of the ivermectin had dissolved. Next, a quantity of closantel amounting to 5% w/v of the final formulation was added, and the mixture was agitated to dissolve a portion of the closantel. With continued agitation, a supplemental amount of N-methyl-2-pyrrolidone was added in a quantity sufficient to dissolve all of the closantel. The total amount of N-methyl-2-pyrrolidone made up the balance of the formulation.

EXAMPLE 6

A quantity of N-methyl-2-pyrrolidone was added to a vessel. Agitation began. With continued agitation, a quantity of a mixture of caprylic acids and esters (obtained from Croda, Inc. of Parsippany, New Jersey under the tradename Crodamol Cap™) amounting to 18% w/v of the final formulation was added, and the mixture was agitated to ensure that all ingredient dissolved. Next, a quantity of isopropyl alcohol amounting to 30% w/v of the final formulation was added and the mixture was agitated until all ingredients were adequately dissolved. Following this, a quantity of diethanolamine amounting to 0.05% w/v of the final formulation was added. Next, a quantity of ivermectin amounting to 0.5% w/v of the final formulation was added and the

- 12 -

mixture was agitated until all components were adequately dissolved into solution. With continued agitation, a quantity of closantel amounting to 5% w/v of the final formulation was added, and the mixture was agitated to dissolve a portion of the closantel. With continued agitation, a supplemental amount of N-methyl-2-pyrrolidone was added in an amount sufficient to completely dissolve all of the closantel. The total amount of N-methyl-2-pyrrolidone made up the balance of the formulation.

EXAMPLE 7

A quantity of propylene glycol was added to a vessel. Agitation began. With continued agitation, a quantity of N-methyl-2-pyrrolidone amounting to 20% w/v of the final formulation was added. Next, a quantity of ethyl oleate amounting to 20% w/v of the final formulation was added, and the mixture was agitated until all ingredients were adequately dissolved. Following this, a quantity of vitamin E acetate amounting to 1% w/v of the final formulation was added. With continued agitation, a quantity of diethanolamine amounting to 0.17% w/v of the final formulation was added. Next, a quantity of xylenes amounting to 40% w/v of the final formulation was added. Next, a quantity of ivermectin amounting to 0.5% w/v of the final formulation was added. Next, a quantity of closantel amounting to 5% w/v of the final formulation was added, and the mixture was agitated to dissolve a portion of the closantel. With continued agitation, a supplemental amount of propylene glycol was then added in an amount sufficient to completely dissolve all of the closantel. The total amount of propylene glycol made up the balance of the formulation.

EXAMPLE 8

A quantity of N-methyl-2-pyrrolidone was added to a vessel. Agitation began. With continued agitation, a quantity of DGME amounting to 40% w/v of the final formulation was added. Next, a quantity of propylene glycol amounting to 10% w/v of the final formulation was added, and the mixture was agitated until all components were adequately dissolved. Subsequently, a quantity of vitamin E acetate amounting to 1% w/v of the final formulation was added. With continued agitation, a quantity of a mixture of caprylic acids and esters (obtained from Croda, Inc. of Parsippany, New Jersey under

- 13 -

the tradename Crodamol Cap™) amounting to 20% w/v of the final formulation was added. Next, a quantity of diethanolamine amounting to 0.05% w/v of the final formulation was added. Following this, a quantity of FD&C Blue #1 amounting to 0.02% w/v of the final formulation was added. A quantity of sterile water amounting to 0.2% w/v of the final formulation was then added. With continued agitation, a quantity of ivermectin amounting to 0.5% w/v of the final formulation was added. Next, a quantity of closantel amounting to 5% w/v of the final formulation was added, and the mixture was agitated to dissolve a portion of the closantel. With continued agitation, a supplemental amount of N-methyl-2-pyrrolidone was then added in an amount sufficient to completely dissolve all of the closantel. The total amount of N-methyl-2-pyrrolidone made up the balance of the formulation.

From the foregoing, it will be seen that this invention is one that is well adapted to attain all the ends and objects herein above set forth together with other advantages which are obvious and inherent to the formulation. It will be understood that certain features and subcombinations are of utility and may be employed without reference to other features and subcombinations. This is contemplated by and is within the scope of the claims. Since many possible embodiments may be made of the invention without departing from the scope thereof, it is to be understood that all matter herein set forth is to be interpreted as illustrative and not in a limiting sense.

I claim:

1. A parasiticidal formulation, comprising the mixture of: at least one pyrrolidone solvent; at least one bridging solvent; and at least one parasiticidal agent.
2. The formulation of claim 1, wherein said parasiticidal agent is
5 selected from the group consisting of closantel, oxclozanide, praziquantel, pyrantels, tetrahydropyrimidines, probenzimidazoles, imidazothiazoles, macrocyclic lactones, benzimidazoles, tetramisoles, avermectins, epsiprantel, morantel, febantel, netobimin, clorsulon, bunamidine, nitroscanate, melarsomine, amidines, benzoyl urea derivatives, carbamates, nitroquanidines, pyrazoles, pyrethrins, pyrethroids, pyriproxyfen,
10 acylhydrazones and any combinations thereof.
3. The formulation of claim 2, wherein said parasiticidal agent is an avermectin selected from the group consisting of ivermectin, moxidectin, doramectin, eprinomectin, and milbemycin.
4. The formulation of claim 2, wherein said parasiticidal agent is a
15 benzimidazole selected from the group consisting of mebendazole, oxibendazole, fenbendazole, oxfendazole, triclabendazole, flubendazole, ricobendazole, thiabendazole, and albendazole.
5. The formulation of claim 2, wherein said parasiticidal agent is comprised of closantel and ivermectin.
- 20 6. The formulation of claim 5, wherein said formulation comprises about 1-10% w/v closantel and about 0.1-5% w/v ivermectin.
7. The formulation of claim 6, wherein said formulation comprises about 3-7% w/v closantel and about 0.3-0.7% w/v ivermectin.

- 15 -

8. The formulation of claim 7, wherein said formulation comprises about 5% w/v closantel and about 0.5% w/v ivermectin.

9. The formulation of claim 1, wherein said pyrrolidone solvent is selected from the group consisting of N-methyl-2-pyrrolidone, 2-pyrrolidone, N,5-
5 dimethyl-2-pyrrolidone, 3,3-dimethyl-2-pyrrolidone, N-ethyl-2-pyrrolidone, N-ethoxy-2-pyrrolidone, N-ethylene-2-pyrrolidone, 1-pyrrolidone, and any combinations thereof.

10. The formulation of claim 9, wherein said formulation comprises 5-90% w/v N-methyl-2-pyrrolidone.

11. The formulation of claim 9, wherein said formulation comprises
10 15-90% w/v 2-pyrrolidone.

12. The formulation of claim 1, wherein said bridging solvent is selected from the group consisting of diethylene glycol monobutyl ether, benzyl benzoate, isopropyl alcohol, xylenes, and any combinations thereof.

13. The formulation of claim 12, wherein said pyrrolidone solvent is
15 2-pyrrolidone and said bridging solvent is xylenes.

14. The formulation of claim 12, wherein said pyrrolidone solvent is N-methyl-2-pyrrolidone and said bridging solvent is diethylene glycol monobutyl ether.

15. The formulation of claim 1, wherein said mixture further comprises at least one solubility agent.

20 16. The formulation of claim 15, wherein said solubility agent is selected from the group consisting of a mixture of caprylic acids and esters, ethyl oleate, propylene glycol, Arachis oil, and any combinations thereof.

17. The formulation of claim 16, wherein said formulation comprises about 5-50% w/v solubility agent.

18. The formulation of claim 15, further comprising: at least one stabilizer.

5

19. The formulation of claim 18, wherein said stabilizer is selected from the group consisting of vitamin B₁₂, vitamin E acetate, niacinamide, ascorbic acid, sodium formaldehyde sulfoxylate, butylated hydroxyaniline, thiocetic acid, sorbic acid, butylated hydroxytoluene, and any combinations thereof.

10 20. The formulation of claim 19, wherein said formulation comprises about 0.005-15% w/v stabilizer.

21. A method of making a parasitocidal formulation, comprising: mixing at least one pyrrolidone solvent and at least one bridging solvent to form a solvent solution; and adding at least one parasitocidal agent to said solvent solution.

15 22. The method of claim 21, further comprising: adding at least one solubility agent to said solvent solution; and adding at least one stabilizer to said solvent solution.

20 23. The method of claim 22, wherein said pyrrolidone solvent is warmed to between about 40 and 80°C, said stabilizer is mixed with said pyrrolidone solvent to form a mixture, said mixture is cooled to room temperature, said bridging solvent is mixed with said cooled mixture to form a solvent solution, said solubility agent is mixed with said solvent solution, and said parasitocidal agent is mixed with said solvent solution until said parasitocidal agent is dissolved.

- 17 -

24. A method for treating an animal having parasites, comprising:
administering to said animal a parasitocidal formulation comprising a mixture of at least
one parasitocidal agent, at least one pyrrolidone solvent, and at least one bridging solvent.

25. The method of claim 24, wherein said parasitocidal formulation is
5 poured onto the skin of said animal and is absorbed through said skin.

26. The method of claim 25, wherein said formulation is poured onto
the skin of said animal in an amount of about 0.02-0.3 milligrams per kilogram of animal.

27. The method of claim 24, wherein said parasitocidal formulation is
injected through the skin of said animal.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US01/04538

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 31/70, 31/44, 31/425, 31/415, 31/355, 31/34, 31/17, 31/115
US CL : 514/30, 52, 355, 367, 393, 394, 395, 458, 474, 595, 596, 694

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/30, 52, 355, 367, 393, 394, 395, 458, 474, 595, 596, 694

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
CAS-ON-LINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	US 6,054,140 A (LAMBERTI) 25 April 2000, see the entire document.	1-27

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

22 MARCH 2001

Date of mailing of the international search report

14 JUN 2001

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

KEVIN E. WEDDINGTON

Telephone No. (703) 308-1235